EUCTR2006-006187-35-FR进行中（未招募）1 期
A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.
aboratoires Merck Sharp & Dohme - Chibret0 个研究点目标入组 1,600 人开始时间: 2007年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patient has at least 1 year history of migraine (with or without aura).
- •Females of child bearing potential must use acceptable contraception throughout trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient is pregnant/breast-feeding (or is a female expecting to conceive during study period).
- •Patient has uncontrolled hypertension (high blood pressure), uncontrolled diabetes, HIV disease, or other significant disease.
- •Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine).
- •Patient has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption.
- •Patient has a history of cancer within the last 5 years.
研究者
相似试验
进行中（未招募）
不适用
A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura. - Study the Safety and Efficacy of MK-0974 in the Acute MigraineMedDRA version: 8.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2006-006187-35-ATMerck Sharp & Dohme GmbH1,600
进行中（未招募）
不适用
A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura. - Study the Safety and Efficacy of MK-0974 in the Acute MigraineMigraineEUCTR2006-006187-35-DEMerck & Co., Inc.1,600
已完成
3 期
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)CTRI/2011/10/002072Merck Sharp Dohme350
进行中（未招募）
3 期
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of PHP When Administered by Continuous Infusion in Patients With Catecholamine-Resistant Distributive ShockA41.9R57Sepsis, unspecifiedShock, not elsewhere classifiedDRKS00000181Apex Bioscience, Inc.377
进行中（未招募）
不适用
A Phase 3 study in Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusEUCTR2012-003626-24-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300